GETI.B

188.7

+0.64%↑

ATT

101.2

+0.2%↑

AMBEA

132.5

+0.08%↑

ARJOB

24.98

-0.24%↓

MSON.B

12.25

+6.06%↑

GETI.B

188.7

+0.64%↑

ATT

101.2

+0.2%↑

AMBEA

132.5

+0.08%↑

ARJOB

24.98

-0.24%↓

MSON.B

12.25

+6.06%↑

GETI.B

188.7

+0.64%↑

ATT

101.2

+0.2%↑

AMBEA

132.5

+0.08%↑

ARJOB

24.98

-0.24%↓

MSON.B

12.25

+6.06%↑

GETI.B

188.7

+0.64%↑

ATT

101.2

+0.2%↑

AMBEA

132.5

+0.08%↑

ARJOB

24.98

-0.24%↓

MSON.B

12.25

+6.06%↑

GETI.B

188.7

+0.64%↑

ATT

101.2

+0.2%↑

AMBEA

132.5

+0.08%↑

ARJOB

24.98

-0.24%↓

MSON.B

12.25

+6.06%↑

Search

Elekta AB

Gesloten

55 -0.99

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

54.75

Max

55.95

Belangrijke statistieken

By Trading Economics

Inkomsten

-220M

10M

Verkoop

169M

4.2B

K/W

Sectorgemiddelde

74.079

57.05

EPS

0.88

Dividendrendement

4.29

Winstmarge

0.236

Werknemers

4,438

EBITDA

111M

640M

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.29%

2.52%

Volgende Winsten

28 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-236M

21B

Vorige openingsprijs

55.99

Vorige sluitingsprijs

55

Elekta AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mrt 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Nike, RH, NCino

31 mrt 2026, 22:35 UTC

Winsten

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisities, Fusies, Overnames

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mrt 2026, 23:50 UTC

Acquisities, Fusies, Overnames

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mrt 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mrt 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mrt 2026, 23:21 UTC

Winsten

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mrt 2026, 23:14 UTC

Marktinformatie
Winsten

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mrt 2026, 23:12 UTC

Marktinformatie

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss Widens >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mrt 2026, 22:36 UTC

Winsten

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mrt 2026, 21:46 UTC

Acquisities, Fusies, Overnames

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mrt 2026, 21:36 UTC

Marktinformatie

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mrt 2026, 21:35 UTC

Winsten

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mrt 2026, 21:33 UTC

Winsten

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mrt 2026, 21:32 UTC

Winsten

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mrt 2026, 21:28 UTC

Winsten

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mrt 2026, 21:26 UTC

Winsten

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mrt 2026, 21:25 UTC

Winsten

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mrt 2026, 21:24 UTC

Marktinformatie
Winsten

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mrt 2026, 21:22 UTC

Winsten

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mrt 2026, 21:22 UTC

Winsten

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mrt 2026, 21:21 UTC

Winsten

Nike's Digital Channel Still Too Promotional, CFO Says

31 mrt 2026, 21:20 UTC

Winsten

Nike CEO: Converse Remains Important to Portfolio

Peer Vergelijking

Prijswijziging

Elekta AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
help-icon Live chat